Suggested remit - To appraise the clinical and cost effectiveness of sodium zirconium cyclosilicate within its marketing authorisation for treating hyperkalaemia
Status In progress
Process STA pre-2018
ID number 1293

Provisional Schedule

Expected publication 21 August 2019

Project Team

Project lead Jeremy Powell

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research


Companies sponsors AstraZeneca
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Kidney Care UK
  Pumping Marvellous Foundation
Professional groups British Society for Heart Failure
  Renal Association
  Royal College of Pathologists
  Royal College of Physicians


Comparator companies none
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
30 May 2019 Committee meeting: 3
26 April 2019 - 20 May 2019 Appraisal consultation: 2
26 March 2019 Committee meeting: 2
29 October 2018 - 19 November 2018 Appraisal consultation
03 October 2018 Committee meeting: 1
09 May 2018 Invitation to participate
24 April 2018 Referral
24 April 2018 In progress, Appraisal referred to NICE.
13 March 2018 - 12 April 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance